BR-LVV

BR-LVV is an investigational gene therapy developed by Ibex Biosciences for the treatment of nervous system diseases, with a primary focus on Parkinson's disease. The therapy utilizes a lentiviral vector (LVV) platform to deliver therapeutic genetic material to target cells. As of March 2025, BR-LVV remains in preclinical development and has not yet entered clinical trials or received regulatory approval. Its mechanism of action is presumed to involve gene transfer via lentiviral vectors, which are commonly used in gene therapies for their ability to stably integrate therapeutic genes into host cell genomes[1][2]. Specific molecular targets or transgenes have not been disclosed.